Author

Julius Pampel

University of California, San FranciscoORCID 0000-0002-3153-1256Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

G.J. CorreyiD· 2 shared James S. FraseriD· 2 shared Adam R. RensloiD· 1 shared Alan AshworthiD· 1 shared Anna K. OrtaiD· 1 shared Brian K. ShoichetiD· 1 shared Edward B. MilleriD· 1 shared Eric R. HantziD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

G.J. CorreyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structural Plasticity and Ligand Promiscuity of CYP3A4 Revealed by Cryo-EM

Anna K. Orta, Jan-Hannes Schäfer, G.J. Correy, Jordan Norman, Julius Pampel, Kate Huddleston, Hugo MacDermott-Opeskin, Edward B. Miller, Gabriella Reggiano, João Rodrigues, Gabriel C. Lander, W. Patrick Walters, James S. Fraser

This study uses cryo-EM to reveal structural plasticity and ligand promiscuity of CYP3A4, showing multiple conformations and highlighting the F/G loop's role in binding pocket remodeling.

bioRxiv · Sep 21, 2026 · PreprintBiophysics

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo

Priyadarshini Jaishankar, G.J. Correy, Yusuke Matsui, Takaya Togo, Moira M. Rachman, Maisie GV Stevens, Eric R. Hantz, Jeffrey Zheng, Morgan E. Diolaiti, Mauricio Montaño, Taha Y. Taha, Julia Rosecrans, Julius Pampel, Nevan J. Krogan, Brian K. Shoichet, , Adam R. Renslo

This paper identifies AVI-6451, an orally bioavailable inhibitor of SARS-CoV-2 Mac1 with once-daily efficacy in a mouse model.

Journal of Medicinal Chemistry · Dec 17, 2025Peer-reviewedPharmacology & Toxicology